retatrutide type 2 diabetes phase 2 trial Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, conducted in the USA 💉 A triple-action once-weekly injection

That warning should change how people interpret online offers

Pharmacol Res [Internet]

The North America obesity GLP-1 market size is estimated at USD 4.93 billion in 2025 and is projected to reach approximately USD 40.27 billion by 2035, with a 23.37% CAGR from 2026 to 2035

The primary causes include reduced caloric intake, electrolyte imbalances, blood sugar fluctuations, and metabolic adaptation to rapid weight loss

What is the weight loss rate of semaglutide GLP-1

The GLP-1 Pro formula provides an unmatched, comprehensive blend of key probiotics, prebiotics, and herbs to support appetite control and curb food cravings